Connect to other sites within the UBM Medica Network
ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.
PD-1 Inhibition Shows Promise in Advanced NSCLC
Inhibition of PD-1 with pembrolizumab was well tolerated and showed promising survival results in a large phase I trial of patients with advanced non–small-cell lung cancer (NSCLC).
Are Prostate and Other Cancer Risks Overestimated?
Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.
Older Early-Stage NSCLC Patients Benefit From Adjuvant Chemotherapy
Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection.
SBRT Offers Short-Term Improvements Over Surgery in Early-Stage NSCLC
Though surgery is the standard treatment for early-stage non-small-cell lung cancer, a new study suggests that stereotactic body radiotherapy offers lower immediate mortality and toxicity.
Annual Lung Cancer Screening Will Be Reimbursed for Select Patients
In this interview we discuss the recent CMS decision to cover low-dose CT screening for lung cancer in patients who fit specific criteria.
Better Fitness Leads to Lower Cancer Risk for Older Men
Men with high midlife cardiorespiratory fitness have a lower incidence of lung and colorectal cancer; however, this association was not seen for prostate cancer.
Crizotinib Yields High Response Rates in ROS1-Rearranged Lung Cancer
A retrospective analysis showed that crizotinib is highly active in lung cancer with ROS1 rearrangements, which are present in about 1% of lung adenocarcinomas.
Oncogenic Drivers in Lung Cancer
From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.
ASCO: Current and Upcoming Lung Cancer Research
Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.
ASCO: Controversies in the Treatment of Mesothelioma of the Pleura
In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.
By clicking Accept, you agree to become a member of the UBM Medica Community.